TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04453826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemo-radiotherapy
Description: 1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy alone
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Study: NCT02610972

Intervention type: DEVICE
Intervention: Congo Red test GV-005
Description: Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.

Intervention type: DEVICE
Intervention: Congo Red test GV-005
Description: Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study: NCT04584398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training with steam inhalation
Study: NCT03961555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG (HyperRab)
Description: it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: it should be administered in deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: it should be administered in deltoid muscle
Study: NCT04525144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebonin Forte
Description: Dietary supplement: Gingko biloba EGb 761
Study: NCT01715389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyAsthma Patient Portal
Description: Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms.
Study: NCT01170273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study: NCT02374060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periocular triamcinolone 40 mg
Description: Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal triamcinolone 4 mg
Description: Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant
Description: • Standard preparation as described for intravitreal injections.
Study: NCT02094118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Point-of-care washed red blood cell transfusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care red blood cell transfusion.
Study: NCT04509570

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: 5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
Study: NCT01121055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
Study: NCT02549989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
Study: NCT02954224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
Study: NCT02478112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable balloon implant
Description: Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
Study: NCT02904369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Study: NCT03671252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME operation
Description: TME operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: efficacy evaluation
Description: chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: efficacy evaluation
Description: chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
Study: NCT02376842

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Severe sepsis early warning best practice alert

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Study: NCT01657604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α2b
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
Study: NCT00418613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK633
Description: MK0633 100mg capsules qd for a 12-wk treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0633 100mg Pbo capsules for a 12-wk treatment period
Study: NCT01227265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant 2 mg or 5 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant 2 mg or 5 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preladenant-matching placebo oral tablet taken twice daily
Study: NCT01139944

Intervention type: GENETIC
Intervention: DNA methylation analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT04671615

Intervention type: DRUG
Intervention: palbociclib
Description: As provided in real world practice
Study: NCT01718964

Intervention type: DRUG
Group type: OTHER
Intervention: Cortisol 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Cortisol 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Mannitol
Description: Mannitol used as placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Mannitol
Description: Mannitol used as placebo
Study: NCT01442701

Intervention type: OTHER
Intervention: Removal of triclosan-containing cleaning products from household.
Description: An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
Study: NCT02281344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 20mg
Description: Supplied as a powder to be prepared as a suspension for oral use
Study: NCT05134506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance for PD® classes
Description: The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
Study: NCT06406270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fava
Description: Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buckwheat
Description: Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
Study: NCT02637635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat transplantation
Description: 100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expander prosthesis
Description: breast reconstruction with expander prosthesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expander prosthesis
Description: breast reconstruction with expander prosthesis.
Study: NCT02881138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Study: NCT01339481

Intervention type: DRUG
Intervention: abatacept
Description: Intravenous Infusion
Study: NCT00397163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation
Study: NCT01462916

Intervention type: DIETARY_SUPPLEMENT
Intervention: honey
Description: A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
Study: NCT00972023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA administration will begin approxiately 14 days prior to surgery.
Study: NCT04193670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: This is a classic dermatological clinical examination during a classic consultation
Study: NCT00972023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical procedure of the invasive breast cancer
Study: NCT02332785

Intervention type: OTHER
Intervention: Data Collection
Description: Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
Study: NCT03183765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).
Study: NCT00002798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT04193670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: This is a classic dermatological clinical examination during a classic consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: 2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: 2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
Study: NCT04466072

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool test for microbial analysis
Description: Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool test for microbial analysis
Description: Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
Study: NCT04335708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postibiotic formulation
Description: 5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
Study: NCT00002798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study: NCT04335708

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formulation
Description: 5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431